PRNewsWire
16 Jul 2026, 10:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Eli Lilly will acquire AtaiBeckley for an upfront cash price of $6.75 per share, representing a 40% premium to the 30-day average trading price. — A definitive acquisition agreement at a significant premium typically drives the target company's stock price toward the offer price immediately.
+0.80Lilly is adding AtaiBeckley's BPL-003, which has FDA Breakthrough Therapy Designation and has initiated Phase 3 activities, to its neuroscience pipeline. — Acquiring a late-stage asset for treatment-resistant depression reduces Lilly's R&D risk and expands its high-growth mental health portfolio.
+0.50The deal includes a Contingent Value Right (CVR) of up to $2.50 per share based on Phase 3 initiation and regulatory approvals for BPL-003 and VLS-01. — The CVR adds potential upside for shareholders but ties a portion of the value to future clinical and regulatory success, introducing uncertainty.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Which stocks this story touches
The company is being acquired at a significant premium of approximately 40% over its average trading price.
The acquisition expands its neuroscience pipeline and adds promising clinical-stage mental health therapies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
1h ago
